Quantcast

Stocks Generating Improved Relative Strength: Smith & Nephew


Shutterstock photo

Smith & Nephew ( SNN ) had its Relative Strength ( RS ) Rating upgraded from 69 to 72 Friday -- a welcome improvement, but still short of the 80 or better score you prefer to see.

[ibd-display-video id=2385970 width=50 float=left autostart=true] This unique rating identifies technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.

History shows that the top-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Smith & Nephew can continue to show renewed price strength and clear that threshold.

Looking For The Best Stocks To Buy And Watch? Start Here

Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to establish and enter a buying range in heavy trade.

The company reported 16% earnings growth last quarter, while sales growth came in at 0%.

The company earns the No. 35 rank among its peers in the Medical-Products industry group. Abiomed ( ABMD ), Align Technology ( ALGN ) and Inogen ( INGN ) are among the top 5 highly rated stocks within the group.

RELATED:

IBD Stock Rating Upgrades: Rising Relative Strength

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: SNN , RS , ABMD , ALGN , INGN


More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing








Research Brokers before you trade

Want to trade FX?